The integration of structural biology, pharmacology, and translational studies will be essential to harness the full therapeutic potential of this multifaceted hormone, not only for the obesity treatment in the post-GLP-1 receptor agonist era, but also in the management of inflammatory diseases, neuropsychiatric disorders, and addiction-related therapy. The gene discussed is GLP1R; the disease is obesity disorder.